MHRA Largest Seizure of Unlicensed Weight Loss Medicines
Review adverse event reports for potential links to counterfeit weight loss medicines; check product supply chain for unlicensed sources.
2 SOPs may need review
Health Canada lists FRM-0360A/FRM-0360B for device recall reporting and shows GUI-0102 GVP guidance issued/implemented May 22, 2026.
Health Canada update requires triage for Local Affiliate Compliance, Device Vigilance, Inspection Readiness; confirm local obligations and document follow-up actions.
Local Safety Officer
Immediate triage (within 1 business day), then weekly review until closure.
Primary-source confirmation recommended before operational implementation.
Health Canada lists FRM-0360A/FRM-0360B for device recall reporting and shows GUI-0102 GVP guidance issued/implemented May 22, 2026.
Potential impact spans Local Affiliate Compliance, Device Vigilance, Inspection Readiness, Regulatory Intelligence Monitoring, so Local Safety Officer oversight is needed to maintain compliance readiness and evidence traceability.
Health Canada update requires triage for Local Affiliate Compliance, Device Vigilance, Inspection Readiness; confirm local obligations and document follow-up actions.
Review adverse event reports for potential links to counterfeit weight loss medicines; check product supply chain for unlicensed sources.
2 SOPs may need review
Review product inventory for Tawon Liar; report any adverse events to FDA MedWatch; consider adding product to signal monitoring list; ensure labeling compliance checks for similar products.
2 SOPs may need review
Immediately quarantine and return unused MonaTherm probes from affected lots; review patient records for potential exposure and adverse events.
2 SOPs may need review
Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.
2 SOPs may need review